5 recruiting, 4 completed, 3 unknown, 2 active not recruiting. 13 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Recruiting 4, Completed 3, Unknown 3, Active not recruiting 2, Withdrawn 1 |
| Phase 1 | 3 | Active not recruiting 1, Completed 1, Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Daratumumab Injection: new trials by email Literature Review of Daratumumab Injection trials Research Report on Daratumumab Injection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Daratumumab for T Cell ALL With MRD-positive After Standard Chemotherapy Daratumumab Injection - ALL, Adult | Phase 2 | Withdrawn | Institute of Hematology & Blood Diseases Hospital, China | 2025-12-01 | 2026-05-13 | |
| Subcutaneous Daratumumab Administration in the Thigh Vs Abdomen in Plasma Cell Disorders Daratumumab Injection - Plasma Cell Disorder | Phase 1 / Phase 2 | Recruiting | University of Maryland, Baltimore | 30 | 2025-10-23 | 2026-10-29 |
| Anti-CD38 Antibody Treating Elderly Patients With Primary Immune Thrombocytopenia (ITP) Daratumumab Injection - Immune Thrombocytopenia, Treatment | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 30 | 2025-08-01 | 2025-07-14 |
| Anti-CD38 Antibody Treating Children With Primary Immune Thrombocytopenia (ITP) Daratumumab Injection - Immune Thrombocytopenia, Treatment | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 30 | 2024-08-01 | 2025-08-05 |
| FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM) Daratumumab Injection, Dexamethasone, Lenalidomide capsule - Multiple Myeloma | Phase 3 | Recruiting | Stichting Hemato-Oncologie voor Volwassenen Nederland | 599 | 2024-05-14 | 2024-08-19 |
| Use of a New Medicine "Daratumumab" to Treat Left-over Cancer in a Blood Cancer Called "T Acute Lymphoblastic Leukemia" Daratumumab Injection - T Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | Tata Memorial Centre | 18 | 2023-08-28 | 2025-06-15 |
| A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX15 With Daratumumab in Male Subjects HLX15, US-sourced DARZALEX®, CN-sourced DARZALEX® - Multiple Myeloma | Phase 1 | Completed | Shanghai Henlius Biotech | 172 | 2023-01-31 | 2024-06-28 |
| A Clinical Trial to Assess Safety and Efficacy of Daratumumab in the Treatment of Primary Immune Thrombocytopenia Daratumumab Injection - Immune Thrombocytopenia | Phase 2 | Unknown | Institute of Hematology & Blood Diseases Hospital, China | 60 | 2022-12-10 | 2025-05-28 |
| Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis Venetoclax Oral Tablet, 200 mg, FISH assay, Venetoclax Oral Tablet, 400 mg - AL Amyloidosis | Phase 1 / Phase 2 | Active not recruiting | Columbia University | 53 | 2022-10-26 | 2026-10-08 |
| An Open Label Study to Evaluate Daratumumab in Participants With Moderate to Severe Systemic Lupus Erythematosus Daratumumab Injection - Systemic Lupus Erythematosus | Phase 2 | Unknown | Charite University, Berlin, Germany | 10 | 2021-06-30 | 2021-03-23 |
| The DART Study- Daratumumab Treatment in ITP Daratumumab Injection - ITP | Phase 2 | Unknown | Ostfold Hospital Trust | 21 | 2021-01-21 | 2024-04-09 |
| Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM Lenalidomide, Ixazomib, Daratumumab Injection - Myeloma, Multiple | Phase 2 | Active not recruiting | Alliance Foundation Trials, LLC. | 79 | 2020-10-21 | 2025-12-18 |
| Treatment of POEMS Syndrome With Daratumumab Daratumumab Injection - POEMS Syndrome | Phase 2 | Completed | University of Arkansas | 2 | 2020-09-22 | 2023-11-13 |
| Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma Daratumumab Injection, Dexamethasone Oral, Lenalidomide Pill - Multiple Myeloma | Phase 2 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 33 | 2019-11-22 | 2026-08-20 |
| Study of Daratumumab in Patients With Mild to Moderate Alzheimer's Disease Daratumumab Injection - Alzheimer Disease | Phase 2 | Completed | Marc L Gordon, MD | 16 | 2019-11-06 | 2025-11-14 |
Multiple Myeloma (4) · Purpura, Thrombocytopenic, Idiopathic (3) · Neoplasms, Plasma Cell (2) · Alzheimer Disease (1) · Immunoglobulin Light-chain Amyloidosis (1) · Lupus Erythematosus, Systemic (1) · Neoplasm, Residual (1) · POEMS Syndrome (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1) · Proteostasis Deficiencies (1)
Institute of Hematology & Blood Diseases Hospital, China (4) · Alliance Foundation Trials, LLC. (1) · Charite University, Berlin, Germany (1) · Columbia University (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Marc L Gordon, MD (1) · Ostfold Hospital Trust (1) · Shanghai Henlius Biotech (1) · Stichting Hemato-Oncologie voor Volwassenen Nederland (1) · Tata Memorial Centre (1) · University of Arkansas (1) · University of Maryland, Baltimore (1)
United States (6) · China (4) · Denmark (1) · France (1) · India (1) · Netherlands (1) · Norway (1)
Lei Zhang, MD (2) · Andrew Yee, MD (1) · Ashraf Badros, MD (1) · Evanthia Galanis, MD (1) · Frits van Rhee, MD (1) · Hui Wei, doctor (1) · Lei Zhang, M.D. (1) · Rachid C Baz, MD (1) · Rajshekhar Chakraborty, MD (1) · Sonja Zweegman, Prof Dr MD (1) · Sumeet Mirgh, MD, DM (1) · Tobias Alexander, MD (1) · Waleed Ghanima, PhD (1) · Yunfei Chen, MD (1)
PMID 16195338, PMID 19141862, PMID 21719599, PMID 22442346, PMID 25966987, PMID 25999452, PMID 26308596, PMID 27216216, PMID 27618682, PMID 27913532, PMID 28494052, PMID 29127588, PMID 29305553, PMID 29358182, PMID 29884853, PMID 30037340, PMID 30498492, PMID 31435023, PMID 31452197, PMID 32244252, PMID 32439800, PMID 32619115, PMID 32653327, PMID 32686081, PMID 32970151, PMID 33026700, PMID 33588922, PMID 33635331, PMID 34151693, PMID 34824885, PMID 35021604, PMID 40226119, PMID 40465397, PMID 40763272, PMID 40983035, PMID 41940000, PMID 42063312
2023 (1)